The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 08, 2022
Filed:
Aug. 19, 2019
Applicant:
Mayo Foundation for Medical Education and Research, Rochester, MN (US);
Inventors:
Lieping Chen, Hamden, CT (US);
Scott E. Strome, Rochester, MN (US);
Eugene D. Kwon, Rochester, MN (US);
Assignee:
Mayo Foundation for Medical Education and Research, Rochester, MN (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); C07K 16/28 (2006.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 38/208 (2013.01); A61K 38/2013 (2013.01); A61K 38/2026 (2013.01); A61K 38/2066 (2013.01); A61K 38/2086 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 38/217 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5088 (2013.01); G01N 33/5091 (2013.01); G01N 33/56972 (2013.01); G01N 33/57407 (2013.01); G01N 33/57438 (2013.01); G01N 33/57484 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01);
Abstract
The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.